Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains

Second-generation anti-CD19-chimeric antigen receptor T cells (anti-CD19-CAR2 T cells) are effective for treating B-cell malignancies; however, anti-CD19-CAR2 T cells can induce human anti-mouse immune responses because anti-CD19 single-chain variable fragment (scFv) in the CAR molecules is derived...

Descripción completa

Detalles Bibliográficos
Autores principales: Wutti-in, Yupanun, Sujjitjoon, Jatuporn, Sawasdee, Nunghathai, Panya, Aussara, Kongkla, Katesara, Yuti, Pornpimon, Yongpitakwattana, Petlada, Thepmalee, Chutamas, Junking, Mutita, Chieochansin, Thaweesak, Poungvarin, Naravat, Yamabhai, Montarop, Yenchitsomanus, Pa-thai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804167/
https://www.ncbi.nlm.nih.gov/pubmed/35117999
http://dx.doi.org/10.3389/fonc.2021.802876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804167/
https://www.ncbi.nlm.nih.gov/pubmed/35117999
http://dx.doi.org/10.3389/fonc.2021.802876

Ejemplares similares